26 results on '"Bachmeier, Christina A"'
Search Results
2. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy
3. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration
4. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
5. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma
6. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
7. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma
8. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
9. Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
10. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
11. Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma
12. Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma
13. Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
14. Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia
15. A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
16. 245 - Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
17. 238 - Outcomes of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma in Patients with Reduced Renal Function Including Dialysis
18. Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy
19. Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel
20. Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel
21. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience
22. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience
23. Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience
24. The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
25. The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy
26. Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.